Cell cycle progression in normal conditions and in glioma. (IMAGE)
Caption
A) Cell cycle progression in patients under normal conditions. The vertical dashes indicate inhibition, and the arrows indicate the flow of biological interactions. Under normal conditions, CDK6 undergoes ubiquitination and subsequent proteasomal degradation, leading to controlled cell cycle arrest at the G1/S checkpoint.
(B) Cell cycle progression in patients with gliomas. The vertical dashes indicate inhibition, and the arrows indicate the flow of biological interactions. In glioblastoma (GBM), enhanced SUMOylation occurs, with SUMO1 binding to CDK6 and stabilizing it. This prevents CDK6 from undergoing ubiquitination and proteasomal degradation, ultimately leading to uncontrolled proliferation of GBM cells.
Credit
Wiktoria Dubanosow, Bartosz Lenda, Marta Żebrowska-Nawrocka, Dagmara Szmajda-Krygier, Rafał Świechowski, Ewa Balcerczak
Usage Restrictions
Credit must be given to the creator. Only noncommercial uses of the work are permitted. No derivatives or adaptations of the work are permitted.
License
CC BY-NC-ND